Trial Profile

Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MEDI 570 (Primary)
Indications Cutaneous T-cell lymphoma; Follicular lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Adverse reactions; First in man

Most Recent Events

27 Dec 2024 Planned End Date changed from 18 Dec 2025 to 20 Dec 2025.
20 Dec 2024 Planned End Date changed from 28 Feb 2025 to 18 Dec 2025.
01 Mar 2024 Planned End Date changed from 31 Dec 2023 to 28 Feb 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com